Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 10/20 | 0.58 |
| ▸ | MTNR1B | P49286 | 10/20 | 0.58 |
| ▸ | GBA1 | P04062 | 1/20 | 0.49 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.47 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1206387 | 0.85 | GBA1 (0.51) | MTNR1AMTNR1BGBA1BCAT2PRMT3 | |
| SCHEMBL14861144 | 0.85 | GBA1 (0.51) | MTNR1AMTNR1BGBA1BCAT2PRMT3 | |
| SCHEMBL14861146 | 0.85 | GBA1 (0.51) | MTNR1AMTNR1BGBA1BCAT2PRMT3 | |
| Hydrochloric Acid SCHEMBL9716119 | 0.83 | GBA1 (0.50) | MTNR1AMTNR1BGBA1BCAT2PRMT3 | |
| SCHEMBL8528168 | 0.83 | BCAT2 (0.68) | GBA1BCAT2PRMT3NPC1RAB9A | |
| SCHEMBL2091812 | 0.82 | MTNR1A (0.67) | MTNR1AMTNR1BBCAT2NPC1RAB9A | |
| SCHEMBL3343976 | 0.82 | TSHR (0.43) | MTNR1AMTNR1BNPC1 | |
| SCHEMBL3343979 | 0.82 | TSHR (0.43) | MTNR1AMTNR1BNPC1 | |
| SCHEMBL4989290 | 0.82 | GBA1 (0.50) | MTNR1AMTNR1BGBA1BCAT2PRMT3 | |
| SCHEMBL390578 | 0.82 | ADRB2 (0.47) | MTNR1AMTNR1BNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104470523-B | Compound based on imidazo [1,2 b] pyridazine, comprising their compositions and its application method | 莱西肯医药有限公司 | 2017-07-11 | — | — | CN | disclosed |
| US-7393958-B2 | Triamide-substituted heterobicyclic compounds | PFIZER, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7368573-B2 | Triamide-substituted heterobicyclic compounds | PFIZER INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2007-04-26 | — | — | US | disclosed |
| EP-1716137-A1 | SUBSTITUTED QUINOLINE COMPOUNDS | Pfizer Products Incorporated (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | BERTINATO PETER | 2006-10-05 | — | — | US | disclosed |
| WO-2005080373-A1 | SUBSTITUTED QUINOLINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | APOB, MTPN, CTRB1 | MTNR1A 536/4885MTNR1B 72/4885GBA1 426/4885 |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | APOB, MTPN, CTRB1 | MTNR1A 536/4885MTNR1B 72/4885GBA1 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.